IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Manny Gugliuzza who wrote (293)	3/20/1998 7:32:00 AM
From: Easy Mark	Read Replies (1) of 1510

IRC Web site lists disease population for AIDS as United States 1.5 million, Worldwide 20 million. Thus 250,000 cases would be less than 20% market share. At $3200/year/patient, the total revenue would be about $800,000,000. That would result in earnings of about $40/share. In order to get to earnings of $0.50/share IRC would need revenues of about $50 million. That level would be achieved with about 16,000 patients. I would guess there are already 3-5,000 patients using Remune. Upon FDA approval, the costs of Remune treatment for those patients should be reimbursable insurance coverage. This level of market penetration seems pretty modest, do you agree.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next